News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
ZIOPHARM, Inc. Commences Treatment of First Patients in Two Separate Phase I/II Combination Studies of Both Indibulin and Palifosfamide
February 4, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
NEW YORK--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP), announced today that dosing of the first patient took place in two separate new studies, including:
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 1
MORE ON THIS TOPIC
Duchenne muscular dystrophy
Dyne Plans Post-Prasad FDA Run as Duchenne Exon Skipper Sustains Benefit in Long Term Data
March 10, 2026
·
3 min read
·
Tristan Manalac
IgA nephropathy
Vertex’s Nephropathy Asset Delivers ‘Strong’ Late-Stage Data, Clears Path to FDA
March 10, 2026
·
2 min read
·
Tristan Manalac
Insights
Single Pivotal Trials Demand Stronger Data and Risk Strategies
March 10, 2026
·
3 min read
·
Jennifer C. Smith-Parker
Obesity
AbbVie’s Amylin Candidate ‘Competitive’ in Early-Stage Trial
March 9, 2026
·
2 min read
·
Heather McKenzie
